Sign up for the MPE webinar on ASH 2023 myeloma and AL amyloidosis highlightsAL amyloidosis, Conferences, MPE, MyelomaDecember 9, 2023
The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myelomaAccess, MyelomaDecember 8, 2023
MPE launches a report focused on the impact of AL amyloidosis in quality of lifeAL amyloidosis, MPENovember 21, 2023
ESMO 2023 | Patient Advocacy Track highlights challenges in access, caregiver support and digitalisationConferences, MPEOctober 27, 2023
MPE launches European Amyloidosis Diagnosis Pathway to promote early detection of the rare diseaseAccess, AL amyloidosisOctober 26, 2023
MPE to present at European Society for Medical Oncology (ESMO) Annual Congress 2023Conferences, MPEOctober 17, 2023
EMA CHMP gives positive recommendation to elranatamab for the treatment of relapsed or refractory myelomaAccess, MPE, MyelomaOctober 13, 2023
